A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19
Study of Remdesivir in Participants Hospitalized with Severe COVID-19
Sponsor: Gilead
Enrolling: Male and Female Patients
IRB Number: AAAS9614
U.S. Govt. ID: NCT04292899
Contact: Allison Wolf: 212-342-4412 / aw2565@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test a medication to treat COVID-19 called remdesivir (RDV) that has not yet been approved by the FDA. If you choose to take part in this study, you will continue to receive the standard care for COVID-19. In addition, you will be randomized to either a 5-day or a 10-day treatment with RDV intravenously (by vein in the arm). You will be in this study for 28 days, or until you leave the hospital or clinic, whichever is earlier. This does not include the screening period which can last up to 3 days.
This study is closed
Investigator
Max O'Donnell, MD, MPH
Do You Qualify?
Is the patient 12 years of age or older? Yes No
Has the patient tested positive for COVID-19? Yes No
Is the patient currently hospitalized and require medical care for COVID-19? Yes No
Does the patient currently require mechanical ventilation? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Allison Wolf
aw2565@cumc.columbia.edu
212-342-4412
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE